Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $142K | $4.36M | $4.42M | $5.78M | $9.38M | $4.33M | $12.0M | $9.76M | $11.7M | $11.5M |
| Revenue growth | — | 2981.6% | 1.3% | 30.8% | 62.5% | -53.8% | 175.8% | -18.4% | 19.8% | -1.5% |
| Operating income | -$13.6M | -$34.2M | -$30.8M | -$28.9M | -$26.6M | -$40.7M | -$34.4M | -$34.3M | -$30.8M | -$45.9M |
| Operating margin | -9599.8% | -785.3% | -698.0% | -501.3% | -283.9% | -939.1% | -287.8% | -351.3% | -263.8% | -398.8% |
| Net income | -$14.7M | -$22.0M | -$32.1M | -$38.5M | -$33.8M | -$52.6M | -$47.5M | -$41.3M | -$38.5M | -$53.6M |
| Net margin | -10410.9% | -503.7% | -727.9% | -667.3% | -360.2% | -1213.4% | -396.9% | -423.1% | -329.3% | -465.4% |
| EPS (diluted) | -$1.35 | -$7.59 | -$153.27 | -$9.01 | -$3.00 | -$88.22 | -$36.18 | -$2,678.17 | -$130.69 | -$22.97 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.4M | -$9.82M | -$22.7M | -$20.5M | -$15.3M | -$35.0M | -$33.1M | -$33.2M | -$29.4M | -$23.7M |
| Capital expenditures | $104K | — | $6.53K | — | $7.00K | $6.00K | $77.0K | — | $16.0K | — |
| Free cash flow | -$14.5M | — | -$22.7M | — | -$15.3M | -$35.0M | -$33.2M | — | -$29.4M | — |
| Share buybacks | — | — | $30.00 | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $951K | $521K | $2.57M | $3.50M | $8.09M | $17.1M | $5.47M | $6.47M | $8.00M | $968K |
| Total assets | $3.56M | $43.6M | $41.0M | $36.4M | $42.8M | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Total liabilities | $6.02M | $26.4M | $26.7M | $15.8M | $25.6M | $41.4M | $48.8M | $45.9M | $44.4M | $57.0M |
| Long-term debt | $1.82M | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | -$2.45M | $17.3M | $5.38M | $10.7M | $17.2M | $11.9M | -$1.36M | $4.90M | $6.49M | -$18.7M |
| Retained earnings | -$40.4M | -$62.4M | -$94.6M | -$133M | -$167M | -$219M | -$267M | -$308M | -$346M | -$400M |
| Shares (wtd avg diluted) | 14.0M | — | — | — | 12.9M | 596K | 1.31M | 15.4B | 295K | 2.33M |
Every figure is extracted from Jaguar Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.